Access to this symposium is free, but you must first be a
registered FREE ZONE user of HDCN. If you are not already an HDCN FREE ZONE user, please
register at this link and select a username and password.
|
|
 |
Early Intervention for CKD - What's in It for Me?
Sally Campoy, RN, MS, CS, CNN, ANP - Moderator |
 |
|
The Scope of the Cardio-CKD-Anemia Triad
Anton Schoolwerth, MD, MSHA |
|
Building the Collaborative Team: Complementary Roles and Connections
Ann Compton, MSN,
FNP-C, CNN |
|
Food for Thought: Hidden Areas of Noncompliance
Kathy Lane, RD |
|
Psychosocial Components of Patient Care
Renée Bova-Collis, MSW, LCSW |
|
Case Study
Ann Compton, MSN,
FNP-C, CNN |
|
Panel Discussion
All Faculty |
|
Concluding Remarks
Sally Campoy, RN, MS, CS, CNN, ANP - Moderator |
After participating in this program, the learner should be able to:
- Describe a proactive patient management approach to the treatment of patients with CKD to delay and/or prepare
for renal disease progression
- Identify the common complications of CKD, such as anemia; their clinical implications; and management approaches
that can be undertaken
- Discuss the roles and responsibilities of various members of the multidisciplinary care team for CKD patients
|
 |
Sally Campoy, RN, MS, CS, CNN, ANP - Moderator
Nurse Practitioner, Renal Section
Veterans Affairs Medical Center
Denver, Colorado
Anton Schoolwerth, MD, MSHA
Chair, Division of Nephrology
Department of Internal Medicine
Medical College of Virginia
Virginia Commonwealth University
Richmond, Virginia
Ann Compton, MSN, FNP-C, CNN
Family Nurse Practitioner
Division of Nephrology
Medical College of Virginia
Richmond, Virginia
Kathy Lane, RD
Registered Dietitian
GAMBRO Healthcare
Medical College of Virginia
Richmond, Virginia
Renée Bova-Collis, MSW, LCSW
Social Worker
GAMBRO Healthcare
Medical College of Virginia
Richmond, Virginia
|
|
 |
This educational
activity is supported by an educational grant from Ortho Biotech Products, L.P.
Inc. This activity has been planned and produced in accordance with CE
guidelines and policies. From a CE symposium held on May 25, 2002 at the American Nephrology Nurses' Association (ANNA)
Annual Meeting in Orlando, FL. This symposium was approved by ANNA. It was not part of the official ANNA Annual
Meeting.
The series of talks is approved for
2.5 contact hours by the American Nephrology Nurses' Association (ANNA).
|
|
|
Posting Date: October, 2002
CE Credit Eligible Through: October, 2003
Contact Hours/Completion Time: 2.5
Target Audiences: Nurses, nurse practitioners, and other healthcare professionals who treat and manage patients
with CKD.
Method of participation: Listen to the talk, read the PubMed
abstracts linked to data slides and talk references, take the post-test, read
the linked abstracts in the post-test answer feedback material.
|
The prevalence of chronic kidney disease (CKD) is increasing in the US population, particulary in patients with
diabetes and hypertension. The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI)
guidelines define and classify the stages of CKD and stratify the risk for loss of kidney function and the development
of comorbid conditions such as cardiovascular disease (CVD) and anemia. Screening programs, such as the Kidney Early
Evaluation Program (KEEP), as well as prospective, population-based studies, have begun to further quantify the
prevalence of CKD and its comorbidities. The positive outcomes of proactive management of CKD and anemia, as well as
cardiovascular disease, will be examined in this session. The clinical complications of CKD will be discussed, along
with approaches to optimally manage those complications. Collaborative approaches to patient care will be reviewed, and
interdisciplinary care at one institution will be examined through a case study and a panel discussion involving members
of the care team.
This continuing education activity is approved by ANNA
(East Holley Avenue, Box 56, Pitman, New Jersey 08071-0056), an accredited approver by the American Nurses Credentialing Center Commission on Accreditation (ANCC-COA). ANNA is an approved provider of CE
in the following states: California Board of Registered Nursing, BRN Provider No. 00910, Alabama, BRN Provider No. PO324, and the Kansas State Board of Nursing, Provider No. LT0148-0738.
This course offering is applicable for RN and re-LPN licensure in Kansas. Licensees in the state of CA must retain this certificate for 4 years after the CE activity is completed. Other CE states have different mandatory record-keeping requirements. Please be aware of your state's procedure.
The activity provider is HDCN, 15W560 89th St., Hinsdale, IL 60527.
|
FACULTY DISCLOSURE STATEMENTS: |
All faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship with any commercial supporters of the activity. The intent of this disclosure is not to prevent a speaker with a potential conflict of interest from making a presentation but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker's outside interests may influence the presentation with regard to exposition or conclusion.
 Sally Campoy, is a member of the Speakers Bureau for Ortho Biotech Products, L.P.
Anton Schoolwerth, receives grant and/or research support from, is a consultant for, and is a member of the Speakers Bureau for Ortho Biotech Products, L.P.
Ann Compton, is a member of the Speakers Bureaus for Ortho Biotech Products, L.P. and Amgen Inc.
Kathy Lane, has no actual or potential conflicts of interest to disclose.
Renee Bova-Collis, has no actual or potential conflicts of interest to disclose.
|
DISCLOSURE OF UNLABELED USE: |
This
educational activity may contain discussion of published
and/or
investigational uses of agents that are not indicated by
FDA.
The American Nephrology Nurses' Association, and HDCN do not
recommend the use of any agent outside of the labeled
indications.
Please refer to the official prescribing information for
each
product for discussion of approved indications,
contraindications
and warnings.
Participants
have an implied responsibility to use the newly acquired
information
to enhance patient outcomes and their own professional
development.
The information presented in this activity is not meant
to serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment
discussed or suggested in this activity should not be used by clinicians
without evaluation of their patient's conditions and possible
contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
|
|
